Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

BACKGROUND: In RADIANT-4, everolimus showed an improvement of 7.1 months in median progression-free survival (PFS) vs placebo among patients with advanced, well-differentiated, nonfunctional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin. The present analysis focuses on the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, James C, Oh, Do-Youn, Qian, Jiaming, Park, Young Suk, Herbst, Fabian, Ridolfi, Antonia, Izquierdo, Miguel, Ito, Tetsuhide, Jia, Liqun, Komoto, Izumi, Sriuranpong, Virote, Shimada, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400121/
https://www.ncbi.nlm.nih.gov/pubmed/30881026
http://dx.doi.org/10.2147/OTT.S182259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400121/
https://www.ncbi.nlm.nih.gov/pubmed/30881026
http://dx.doi.org/10.2147/OTT.S182259

Ejemplares similares